The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

Liver Cancer

See how Bayer is investigating liver cancer across the pipeline

Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.

Liver cancer icon

Liver Cancer Overview

Bayer’s liver cancer research spans targeted radionuclide therapy, representing distinct scientific approaches being investigated across the oncology portfolio.

These programs connect areas of research with compounds and clinical trials in liver cancer.

1 investigational compound

1 area of research

1 clinical trial

Compound

225Ac-GPC3 (BAY 3547926)

Area of Research

Targeted radionuclide therapy

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Advanced Tumors, Liver Cancer

I

Now Enrolling

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC) (BANTAM-01)

NCT06764316

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.